WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:   || 2 | 3 | 4 | 5 |

«HIGHLIGHTS OF PRESCRIBING INFORMATION - WARNINGS AND PRECAUTIONS -  These highlights do not include all the information needed to use Candida ...»

-- [ Page 1 ] --

HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS -----------------------

These highlights do not include all the information needed to use Candida albicans infection of the mouth and pharynx. Monitor

ASMANEX TWISTHALER safely and effectively. See full patients periodically for signs of adverse effects in the mouth and

prescribing information for ASMANEX TWISTHALER. pharynx.

Advise patients to rinse mouth after inhalation. (5.1) ASMANEX TWISTHALER 110 mcg, 220 mcg (mometasone furoate  Deterioration of asthma or acute episodes: ASMANEX inhalation powder) TWISTHALER should not be used for relief of acute symptoms.

Initial U.S. Approval: 1987 Patients require immediate re-evaluation during rapidly deteriorating asthma. (5.2)

----------------------------INDICATIONS AND USAGE ----------------------------  Hypersensitivity reactions including anaphylaxis, angioedema,

ASMANEX TWISTHALER is a corticosteroid indicated for:

pruritus, and rash have been reported with the use of ASMANEX  Maintenance treatment of asthma as prophylactic therapy in TWISTHALER. Discontinue ASMANEX TWISTHALER if such patients 4 years of age and older. (1.1) reactions occur. (5.3) ASMANEX TWISTHALER is NOT indicated for the relief of acute  Potential worsening of existing tuberculosis; fungal, bacterial, bronchospasm (1.1, 5.2) or in children less than 4 years of age (1.1, viral, or parasitic infection; or ocular herpes simplex. More serious 8.4).

or even fatal course of chickenpox or measles in susceptible patients. Use caution in patients with the above because of the

----------------

–  –  –

2 DOSAGE AND ADMINISTRATION

Administer ASMANEX TWISTHALER by the orally inhaled route only. Instruct patients to inhale rapidly and deeply. Advise patients to rinse the mouth after inhalation. Individual patients will experience a variable time to onset and degree of symptom relief. Maximum benefit may not be achieved for 1 to 2 weeks or longer after initiation of treatment. After asthma stability has been achieved, it is desirable to titrate to the lowest effective dosage to reduce the possibility of side effects. For patients ≥12 years of age who do not respond adequately to the starting dose after 2 weeks of therapy, higher doses may provide additional asthma control. The safety and efficacy of ASMANEX TWISTHALER when administered in excess of recommended doses have not been established.

2.1 Recommended Dosages in Patients 4 Years of Age and Older The recommended starting doses and highest recommended daily dose for ASMANEX TWISTHALER treatment based on prior asthma therapy are provided in Table 1.

–  –  –

3 DOSAGE FORMS AND STRENGTHS

ASMANEX TWISTHALER is a dry powder for inhalation that is available in 2 strengths.

ASMANEX TWISTHALER 220 mcg delivers 200 mcg mometasone furoate per actuation from the mouthpiece.

ASMANEX TWISTHALER 110 mcg delivers 100 mcg mometasone furoate per actuation from the mouthpiece.

4 CONTRAINDICATIONS

4.1 Status Asthmaticus ASMANEX TWISTHALER therapy is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.

4.2 Hypersensitivity ASMANEX TWISTHALER is contraindicated in patients with known hypersensitivity to milk proteins or any ingredients of ASMANEX TWISTHALER [see Warnings and Precautions (5.3) and Description (11)].

5 WARNINGS AND PRECAUTIONS

5.1 Local Effects In clinical trials, the development of localized infections of the mouth and pharynx with Candida albicans occurred in 195 of 3007 patients treated with ASMANEX TWISTHALER. If oropharyngeal candidiasis develops, it should be treated with appropriate local or systemic (i.e., oral) antifungal therapy while remaining on treatment with ASMANEX TWISTHALER therapy, but at times therapy with the ASMANEX TWISTHALER may need to be interrupted. Advise patients to rinse the mouth after inhalation of ASMANEX TWISTHALER.

5.2 Acute Asthma Episodes ASMANEX TWISTHALER is not a bronchodilator and is not indicated for rapid relief of bronchospasm or other acute episodes of asthma. Instruct patients to contact their physician immediately if episodes of asthma that are not responsive to bronchodilators occur during the course of treatment with ASMANEX TWISTHALER. During such episodes, patients may require therapy with oral corticosteroids.

5.3 Hypersensitivity Reactions Including Anaphylaxis Hypersensitivity reactions including rash, pruritus, angioedema, and anaphylactic reaction have been reported with use of ASMANEX TWISTHALER. Discontinue ASMANEX TWISTHALER if such reactions occur [see Contraindications (4.2) and Adverse Reactions (6.2)].

ASMANEX TWISTHALER contains small amounts of lactose, which contains trace levels of milk proteins. In postmarketing experience with ASMANEX TWISTHALER, anaphylactic reactions in patients with milk protein allergy have been reported [see Contraindications (4.2) and Adverse Reactions (6.2)].

5.4 Immunosuppression Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In such children or adults who have not had these diseases or who are not properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for

–  –  –





Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

5.5 Transferring Patients from Systemic Corticosteroid Therapy Particular care is needed for patients who are transferred from systemically active corticosteroids to ASMANEX TWISTHALER because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA) function.

Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although ASMANEX TWISTHALER may improve control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of corticosteroid systemically and does NOT provide the mineralocorticoid activity necessary for coping with these emergencies.

During periods of stress or severe asthma attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instruction. These patients should also be instructed to carry a medical identification card indicating that they may need supplementary systemic corticosteroids during periods of stress or severe asthma attack.

Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to ASMANEX TWISTHALER. Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during treatment with ASMANEX TWISTHALER [see Dosage and Administration (2.1)]. Lung function (FEV1 or PEFR), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition to monitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenal insufficiency such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.

Transfer of patients from systemic corticosteroid therapy to ASMANEX TWISTHALER may unmask allergic conditions previously suppressed by the systemic corticosteroid therapy, e.g., rhinitis, conjunctivitis, eczema, arthritis, and eosinophilic conditions.

During withdrawal from oral corticosteroids, some patients may experience symptoms of systemically active corticosteroid withdrawal, e.g., joint and/or muscular pain, lassitude, and depression, despite maintenance or even improvement of respiratory function.

5.6 Hypercorticism and Adrenal Suppression ASMANEX TWISTHALER will often help control asthma symptoms with less suppression of HPA function than therapeutically similar oral doses of prednisone. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing ASMANEX TWISTHALER. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response. It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear in a small number of patients, particularly when ASMANEX TWISTHALER is administered at higher than recommended doses over prolonged periods of time. If such effects occur, the dosage of ASMANEX TWISTHALER should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids and for management of asthma.

4

5.7 Reduction in Bone Mineral Density Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids, including mometasone furoate. The clinical significance of small changes in BMD with regard to long-term outcomes is unknown. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care.

In a 2-year double-blind study in 103 male and female asthma patients 18 to 50 years of age previously maintained on bronchodilator therapy (baseline FEV1 85%-88% predicted), treatment with ASMANEX TWISTHALER 220 mcg twice daily resulted in significant reductions in lumbar spine (LS) BMD at the end of the treatment period compared to placebo. The mean change from baseline to endpoint in the lumbar spine BMD was -0.015 (-1.43%) for the ASMANEX TWISTHALER group compared to 0.002 (0.25%) for the placebo group. In another 2-year double-blind study in 87 male and female asthma patients 18 to 50 years of age previously maintained on bronchodilator therapy (baseline FEV1 82%-83% predicted), treatment with ASMANEX TWISTHALER 440 mcg twice daily demonstrated no statistically significant changes in lumbar spine BMD at the end of the treatment period compared to placebo. The mean change from baseline to endpoint in the lumbar spine BMD was -0.018 (-1.57%) for the ASMANEX TWISTHALER group compared to -0.006 (-0.43%) for the placebo group.

5.8 Effect on Growth Orally inhaled corticosteroids, including ASMANEX TWISTHALER, may cause a reduction in growth velocity when administered to pediatric patients. Monitor the growth of pediatric patients receiving ASMANEX TWISTHALER routinely (e.g., via stadiometry). To minimize the systemic effects of orally inhaled corticosteroids, including ASMANEX TWISTHALER, titrate each patient’s dose to the lowest dosage that effectively controls his/her symptoms [see Use in Specific Populations (8.4)].

5.9 Glaucoma and Cataracts In clinical trials, glaucoma, increased intraocular pressure, and cataracts have been reported in 8 of 3007 patients following the administration of ASMANEX TWISTHALER. Close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.

5.10 Paradoxical Bronchospasm As with other inhaled asthma medications, bronchospasm may occur with an immediate increase in wheezing after dosing. If bronchospasm occurs following dosing with ASMANEX TWISTHALER, it should be treated immediately with a fast-acting inhaled bronchodilator.

Treatment with ASMANEX TWISTHALER should be discontinued and alternative therapy instituted.

6 ADVERSE REACTIONS

Systemic and local corticosteroid use may result in the following:

 Candida albicans infection [see Warnings and Precautions (5.1)]  Immunosuppression [see Warnings and Precautions (5.4)]  Hypercorticism and adrenal suppression [see Warnings and Precautions (5.6)]  Growth effects [see Warnings and Precautions (5.8) and Use in Specific Populations (8.4)]  Glaucoma and cataracts [see Warnings and Precautions (5.9)]

6.1 Clinical Studies Experience The safety data described below reflect exposure to ASMANEX TWISTHALER in 2380 patients with asthma exposed for 8 to 12 weeks and 627 patients with asthma exposed for 1 year in a total of 17 clinical trials.

In adult and adolescent patients 12 years of age and older, ASMANEX TWISTHALER was studied in 10 placebo-controlled clinical trials of 8 to 12 weeks duration with a total of 1750 patients receiving 5 ASMANEX TWISTHALER. There were also 3 trials with a total of 475 patients receiving ASMANEX TWISTHALER for 1 year. In the 8- to 12-week clinical trials, the population was 12 to 83 years of age;



Pages:   || 2 | 3 | 4 | 5 |


Similar works:

«Sample Study of Informal Scrap Dealers and Recyclers in Bangalore February –April 2011 Contents Background Page 1 Methodology Page 3 Survey Findings Page 5 Map Page 13 Case Studies Page 14 Conclusion Page 22 Annexure Annexure 1Survey questionnaires Page 25 Questionnaire for small/ medium scrap shops study Page 25 Bangalore 2011 Questionnaire for Large scrap shops study Page 26 Bangalore 2011 Interview with Reprocessor Page 28 Annexure 2Maps Page 29 Background India has an age old practice of...»

«Cordarone® (amiodarone HCl) TABLETS Rx only DESCRIPTION Cordarone (amiodarone HCl) is a member of a new class of antiarrhythmic drugs with predominantly Class III (Vaughan Williams' classification) effects, available for oral administration as pink, scored tablets containing 200 mg of amiodarone hydrochloride. The inactive ingredients present are colloidal silicon dioxide, lactose, magnesium stearate, povidone, starch, and FD&C Red 40. Cordarone is a benzofuran derivative:...»

«Abortion, Infanticide, and the Social Rhetoric of the Apocalypse of Peter Gray, Patrick. Journal of Early Christian Studies, Volume 9, Number 3, Fall 2001, pp. 313-337 (Article) Published by The Johns Hopkins University Press DOI: 10.1353/earl.2001.0042 For additional information about this article http://muse.jhu.edu/journals/earl/summary/v009/9.3gray.html Access Provided by Emory University Libraries at 04/27/10 3:31PM GMT GRAY/SOCIAL RHETORIC OF THE APOCALYPSE OF PETER 313 Abortion,...»

«when co-administered with other serotonergic agents (including triptans, HIGHLIGHTS OF PRESCRIBING INFORMATION tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, These highlights do not include all the information needed to use Savella buspirone and St. John’s Wort). If such symptoms occur, discontinue safely and effectively. See full prescribing information for Savella. Savella and initiate supportive treatment. If concomitant use of Savella with other serotonergic drugs is...»

«30029-XX Entocort® EC (budesonide) Capsules Rx only DESCRIPTION Budesonide, the active ingredient of ENTOCORT® EC capsules, is a synthetic corticosteroid. It is designated chemically as (RS)­ 11β, 16α, 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde. Budesonide is provided as a mixture of two epimers (22R and 22S). The empirical formula of budesonide is C25H34O6 and its molecular weight is 430.5. Its structural formula is: C H 2O H C O CH3 H O HO C O...»

«Rev. Claire Feingold Thoryn Theme: “Gratitude” Sermon: “Give It Away” November 22, 2015 (Reverse Offering Service) Call to Worship The prophet Mohammed was asked “What actions are most excellent?” And he replied: “To gladden the heart of a human being. To feed the hungry. To help the afflicted. To lighten the sorrow of the sorrowful. To remove the wrongs of the injured. That person is the most beloved of God who does the most good to God’s creatures.” Let us join together with...»

«© 2010 The two sisters build the Twelve Tribes of Israel, and bear a positive influence on each other. by Dina Coopersmith When we last left off, Rachel was learning a tough lesson in the realities of life as a matriarch: Why were the matriarchs barren? Because God desires the prayers and conversations of the righteous. He said: “They are beautiful, they are rich; if I give them children, when will I ever hear from them? (Midrash Tanchuma Toldot 9) It's not easy being a matriarch! Of the...»

«Argyll and Bute Council Development Services Delegated or Committee Planning Application Report and Report of handling as required by Schedule 2 of the Town and Country Planning (Development Management Procedure) (Scotland) Regulations 2008 relative to applications for Planning Permission or Planning Permission in Principle Reference No: 13/02685/NMA Planning Hierarchy: Local Applicant: Mr Barry Adamson Proposal: Non material amendment to Planning Permission 12/02792/PP (Erection of a building...»

«Courtesy of John Devaney at www.fullpointsfooty.net 1961 SANFL Grand Final: West Adelaide vs. Norwood The Turkish Bath Grand Final Link Bar 1 Norwood's 'Big Bill' Wedding wins a clean tap against Neil Kerley during the course of the 1961 SANFL grand final. Courtesy of John Devaney at www.fullpointsfooty.net Apart from the spectacular fall from grace of 1960 premier North Adelaide, the 1961 SANFL minor round spawned few surprises, and gave rise to the following ladder: 1961 SANFL Premiership...»

«Play Paper Victimization, aggression and sexism in Vijay Tendulkar’s works IJIFR/ V2/ E2/ 010 339-345 English Paper ID Page No Subject Area Vijay Tendulkar, Unmitigated Violence, Mutual Interactions, Human Character, Evil Key Words Inherent, Realistic Display, Projection Play, Torture,Victimization, Helpless Woman Ph. D Research Scholar Raj Kumar. M Karpagam University, Coimbatore Principal (Retd.), Dr. Mummachi Rathinam Arts and Science College, Coimbatore. Abstract Vijay Tendulkar is a...»

«No longer at Ease Chinua Achebe 1 No Longer at Ease First published in 1960 1 For Christie 2 We returned to our places, these Kingdoms, But no longer at ease here, in the old dispensation, With an alien people clutching their gods. I should be glad of another death. T. S. Eliot : 'The Journey of the Magi'. 3 CHAPTER ONE For three or four weeks Obi Okonkwo had been steeling himself against this moment. And when he walked into the dock that morning he thought he was fully prepared. He wore a...»

«HIGHLIGHTS OF PRESCRIBING INFORMATION Wean patients slowly from systemic corticosteroids if transferring These highlights do not include all the information needed to use to ASMANEX HFA. (5.4) ASMANEX HFA safely and effectively. See full prescribing  Hypercorticism and adrenal suppression: May occur with very high information for ASMANEX HFA. dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue ASMANEX HFA slowly. (5.5) ASMANEX® HFA (mometasone...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.